BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc. today announced that results from preclinical studies using its lead compound, JVRS-100, as an immunotherapy to treat acute myelogenous leukemia (AML) were published in the September edition of the journal Cancer Biology & Therapy. JVRS-100 has been shown to induce significant innate immunity resulting in anti-viral, anti-bacterial and anti-cancer effects. A Phase 1 clinical trial of JVRS-100 is currently enrolling subjects at the Penn State Hershey Cancer Institute under the direction of Dr. David Claxton, Professor of Medicine.
